Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Claims for pregabalin (LYRICA) generally match some provided label warnings (dizziness/somnolence, weight gain, and tapering after abrupt/rapid discontinuation) but several statements are not label-supported or overreach beyond the provided excerpts. Melatonin-related claims cannot be verified against the supplied label content because no melatonin FDA labeling text was provided and the provided sections are for LYRICA only.
Category Scores
Accurate Statements
Long-term use of Lyrica (pregabalin) can cause weight gain.
Label excerpt 5.8 Weight Gain: 'LYRICA treatment may cause weight gain.'
Long-term use of Lyrica (pregabalin) can cause dizziness and drowsiness.
Label excerpt 5.5 Dizziness and Somnolence: 'LYRICA may cause dizziness and somnolence.'
It is not recommended to stop taking Lyrica and melatonin suddenly because it can lead to withdrawal symptoms.
Label excerpt 5.6 Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation: 'Following abrupt or rapid discontinuation of LYRICA...' and 'If LYRICA is discontinued, taper... over a minimum of 1 week rather than discontinue... abruptly.'
Unsupported Statements
Lyrica (pregabalin) is a prescription medication used to treat epilepsy, fibromyalgia, and neuropathic pain.
Not fully label-supported for 'epilepsy' broadly. The provided label indications specify adjunctive therapy for 'partial-onset seizures in patients 1 month of age and older,' not a general 'epilepsy' indication.
Lyrica (pregabalin) belongs to the class of medications called gabapentinoids.
No provided FDA label section excerpt supports this classification.
Long-term use of Lyrica (pregabalin) can cause weight gain due to increased appetite and water retention.
Provided label excerpt 5.8 supports weight gain but does not attribute it to 'increased appetite and water retention' in the supplied text.
Long-term use of Lyrica (pregabalin) can cause dizziness and drowsiness.
The supplied label text supports dizziness/somnolence with onset/frequency details, but the provided excerpts do not establish 'long-term use' as the basis of the statement.
Lyrica (pregabalin) can be habit-forming and sudden discontinuation can lead to withdrawal symptoms.
The supplied label excerpt 5.6 discusses symptoms after abrupt/rapid discontinuation and tapering, but the provided text does not describe Lyrica as 'habit-forming' or use 'withdrawal symptoms' in a dependence/withdrawal framing.
Melatonin is an over-the-counter (OTC) supplement.
No melatonin FDA label text was provided to verify OTC status.
Melatonin is generally considered safe when taken in moderate doses.
No FDA label information for melatonin was provided.
Long-term use of melatonin can cause rebound insomnia (where the body becomes dependent on the supplement to fall asleep).
No FDA label information for melatonin was provided.
Melatonin can interact with blood thinners, diabetes medications, and sedatives.
No FDA label information for melatonin was provided; and no LYRICA label excerpt provided supports melatonin interaction claims.
Melatonin can affect hormone levels, particularly in women, leading to changes in menstrual cycles and fertility.
No FDA label information for melatonin was provided.
Taking Lyrica (pregabalin) and melatonin long-term can increase the risk of adverse effects.
No FDA label information provided supports combining LYRICA with melatonin.
Combining Lyrica (pregabalin) and melatonin can cause excessive sedation.
No FDA label information provided supports LYRICA + melatonin sedation risk.
Taking both Lyrica (pregabalin) and melatonin long-term can increase the risk of dependence and withdrawal symptoms.
No FDA label information provided supports dependence/withdrawal framing for melatonin or for the combination.
It is generally not recommended to take both Lyrica and melatonin together because it can increase the risk of adverse effects.
No FDA label information provided supports a recommendation or contraindication regarding melatonin coadministration with LYRICA.
Contradictions
Important Omissions
Key LYRICA FDA label elements (e.g., boxed warnings, contraindications, dosing/renal adjustment, and other warnings/precautions) were not assessed against the provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported melatonin-related interaction/withdrawal/dependence/coadministration risk statements could mislead safety decisions. Partial label-aligned discontinuation tapering applies to LYRICA but the claim extends to melatonin without label support.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements (especially all melatonin-related claims and several LYRICA mechanism/duration/dependence characterizations) are not supported by the supplied FDA label excerpts.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided LYRICA label excerpts (e.g., dizziness/somnolence, weight gain, and LYRICA tapering after abrupt/rapid discontinuation) and remove or qualify all melatonin OTC/safety/interaction/hormone/withdrawal and combination-avoidance claims unless the corresponding melatonin FDA labeling text is provided for verification.